Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of CNTO 7160 in Healthy, Asthma, and Atopic Dermatitis Subjects
NCT02345928Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2014
- Primary completion
- Mar 2017
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of melrilimab in asthma and atopic dermatitis (AD) (13 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Treatment Emergent Adverse Events at Week 21. Started Aug 2014; status: completed.
02
Drugs
melrilimab
03
Conditions
asthmaatopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02345928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02345928.